信息
GEXVal Receives Formal PMDA Opinion Letter for Lead Program GXV-001
2026年3月24日
株式會社GEXValMarch 24, 2026 GEXVal Receives Formal PMDA Opinion Letter for Lead Program GXV-001-Post-Operative De […]
CTO Nakayama Contributes Invited Article to Experimental Medicine, Japan’s Leading Life Science Journal, on AI-Driven Drug Discovery
2026年3月12日
株式會社GEXValMarch 12, 2026 CTO Nakayama Contributes Invited Article to Experimental Medicine Special Issue on AI […]
World Rare Disease Day: GEXVal Presents Posters at 5th Tsukuba Co-creation Conference
2026年3月3日
株式會社GEXValMarch 3, 2026 World Rare Disease Day: GEXVal Presents Two Posters at 5th Tsukuba Co-creation Confere […]
Rare Disease Day Update: FRAXA Features GEXVal’s FRAXA-DVI Completion and FDA Orphan Drug Designation
2026年2月28日
株式會社GEXValFebruary 28, 2026 FRAXA Research Foundation Features GEXVal's Completion of FRAXA-DVI Program and FD […]
GEXVal Selected as Presenting Company at Biotech Showcase™ 2026
2026年1月7日
株式會社GEXValJanuary 7, 2026 GEXVal Selected as Presenting Company at Biotech Showcase™ 2026 GEXVal Inc. (Preside […]